Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Node Pharma AS has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio involves 1 distinct examiner and 1 distinct art unit. With 1 pending office action, the company's current prosecution footprint is minimal, suggesting a targeted approach to its US patent filings. The reliance on 1 distinct art unit means that the examination will likely follow the specific procedural norms and technical expertise of that particular group.
SEAN R DONOHUE is the busiest examiner, managing 1 pending office action. This examiner is the only one currently reviewing the company's applications, making their feedback the central focus of the prosecution team. Practitioners can expect a focused dialogue with SEAN R DONOHUE regarding the technical merits of the application. The concentration of the workload under 1 distinct examiner allows for a consistent communication channel during the prosecution process.
Because there is only 1 pending office action, the company's immediate patent strategy is dependent on the outcome of this matter. The Biotechnology & Pharmaceuticals technology area often involves rigorous examination, and having only 1 distinct art unit involved allows the company to specialize its arguments for that unit's standards. This setup provides a clear path forward for the company's intellectual property goals. The involvement of SEAN R DONOHUE represents the entirety of the company's current examiner interactions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18384509 | MOF FOR RADIOTHERAPY | DONOHUE, SEAN R | 28d |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18384509 | MOF FOR RADIOTHERAPY | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | 28d | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial